These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
59 related articles for article (PubMed ID: 19435660)
21. 3,4-Diarylpiperidines as potent renin inhibitors. Lacombe P; Arbour M; Aspiotis R; Cauchon E; Chen A; Dubé D; Falgueyret JP; Fournier PA; Gallant M; Grimm E; Han Y; Juteau H; Liu S; Mellon C; Ramtohul Y; Simard D; St-Jacques R; Tsui GC Bioorg Med Chem Lett; 2012 Mar; 22(5):1953-7. PubMed ID: 22325946 [TBL] [Abstract][Full Text] [Related]
22. Toluidinesulfonamide hypoxia-induced factor 1 inhibitors: alleviating drug-drug interactions through use of PubChem data and comparative molecular field analysis guided synthesis. Wendt B; Mulbaier M; Wawro S; Schultes C; Alonso J; Janssen B; Lewis J J Med Chem; 2011 Jun; 54(11):3982-6. PubMed ID: 21574568 [TBL] [Abstract][Full Text] [Related]
23. Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2. Caldwell JJ; Welsh EJ; Matijssen C; Anderson VE; Antoni L; Boxall K; Urban F; Hayes A; Raynaud FI; Rigoreau LJ; Raynham T; Aherne GW; Pearl LH; Oliver AW; Garrett MD; Collins I J Med Chem; 2011 Jan; 54(2):580-90. PubMed ID: 21186793 [TBL] [Abstract][Full Text] [Related]
29. From Myricetin to the Discovery of Novel Natural Human ENPP1 Inhibitors: A Virtual Screening, Molecular Docking, Molecular Dynamics Simulation, and MM/GBSA Study. Song S; Shao Z Molecules; 2022 Sep; 27(19):. PubMed ID: 36234712 [TBL] [Abstract][Full Text] [Related]
30. Identification of novel pyrrolopyrimidine and pyrrolopyridine derivatives as potent ENPP1 inhibitors. Jeong HJ; Lee HL; Kim SJ; Jeong JH; Ji SH; Kim HB; Kang M; Chung HW; Park CS; Choo H; Yoon HJ; Kim NJ; Lee DH; Lee SH; Han SJ J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2434-2451. PubMed ID: 36069240 [TBL] [Abstract][Full Text] [Related]
31. Re-awakening Innate Immune Signaling in Cancer: The Development of Highly Potent ENPP1 Inhibitors. Cogan D; Bakhoum SF Cell Chem Biol; 2020 Nov; 27(11):1327-1328. PubMed ID: 33217310 [TBL] [Abstract][Full Text] [Related]
32. Crystal structures of human ENPP1 in apo and bound forms. Dennis ML; Newman J; Dolezal O; Hattarki M; Surjadi RN; Nuttall SD; Pham T; Nebl T; Camerino M; Khoo PS; Monahan BJ; Peat TS Acta Crystallogr D Struct Biol; 2020 Sep; 76(Pt 9):889-898. PubMed ID: 32876064 [TBL] [Abstract][Full Text] [Related]
33. Structure-Aided Development of Small-Molecule Inhibitors of ENPP1, the Extracellular Phosphodiesterase of the Immunotransmitter cGAMP. Carozza JA; Brown JA; Böhnert V; Fernandez D; AlSaif Y; Mardjuki RE; Smith M; Li L Cell Chem Biol; 2020 Nov; 27(11):1347-1358.e5. PubMed ID: 32726585 [TBL] [Abstract][Full Text] [Related]
34. ENPP1, an Old Enzyme with New Functions, and Small Molecule Inhibitors-A STING in the Tale of ENPP1. Onyedibe KI; Wang M; Sintim HO Molecules; 2019 Nov; 24(22):. PubMed ID: 31752288 [TBL] [Abstract][Full Text] [Related]
35. Identification of adenine-N9-(methoxy)ethyl-β-bisphosphonate as NPP1 inhibitor attenuates NPPase activity in human osteoarthritic chondrocytes. Nassir M; Arad U; Lee SY; Journo S; Mirza S; Renn C; Zimmermann H; Pelletier J; Sévigny J; Müller CE; Fischer B Purinergic Signal; 2019 Jun; 15(2):247-263. PubMed ID: 31025169 [TBL] [Abstract][Full Text] [Related]
36. Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) and its inhibitors. Lee SY; Müller CE Medchemcomm; 2017 May; 8(5):823-840. PubMed ID: 30108800 [TBL] [Abstract][Full Text] [Related]
37. Computational Tool for Fast Chemi G; Gemma S; Campiani G; Brogi S; Butini S; Brindisi M Front Chem; 2017; 5():7. PubMed ID: 28503546 [TBL] [Abstract][Full Text] [Related]
38. Substrate-Dependence of Competitive Nucleotide Pyrophosphatase/Phosphodiesterase1 (NPP1) Inhibitors. Lee SY; Sarkar S; Bhattarai S; Namasivayam V; De Jonghe S; Stephan H; Herdewijn P; El-Tayeb A; Müller CE Front Pharmacol; 2017; 8():54. PubMed ID: 28261095 [TBL] [Abstract][Full Text] [Related]
39. Quinazoline-4-piperidine sulfamides are specific inhibitors of human NPP1 and prevent pathological mineralization of valve interstitial cells. Shayhidin EE; Forcellini E; Boulanger MC; Mahmut A; Dautrey S; Barbeau X; Lagüe P; Sévigny J; Paquin JF; Mathieu P Br J Pharmacol; 2015 Aug; 172(16):4189-99. PubMed ID: 26031197 [TBL] [Abstract][Full Text] [Related]